Option Care Health, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. Option Care Health provides infusion therapy and related services through a U.S. network of pharmacies and ambulatory infusion suites, serving patients in homes and other nonhospital settings.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $1,093.0 million | $1,020.9 million | $3,177.9 million | $2,917.5 million |
| Gross profit / margin | $254.3 million / 23.3% | $218.0 million / 21.4% | $734.1 million / 23.1% | $635.8 million / 21.8% |
| Operating income / margin | $81.0 million / 7.4% | $60.7 million / 5.9% | $230.0 million / 7.2% | $172.0 million / 5.9% |
| Net income | $56.3 million | $38.8 million | $209.9 million | $103.0 million |
| Diluted EPS | $0.31 | $0.21 | $1.16 | $0.57 |
For the first nine months, operating cash flow was $320.3 million, versus $224.1 million a year earlier. Investing cash outflow was $40.7 million, including $22.0 million of property and equipment purchases; financing cash outflow was $187.3 million, largely reflecting stock repurchases. Cash increased by $92.3 million to $386.5 million.
At September 30, 2023, debt principal totaled $1,089.5 million (including a $589.5 million term loan and $500.0 million of senior notes). The term loan’s stated interest rate was 8.20%; the notes bear 4.375%. Net carrying value of debt was $1,063.0 million. The company reported $219.7 million of available borrowing capacity under its credit facilities, net of outstanding letters of credit.
Changes and drivers
- Q3 revenue grew 7.1% year over year; nine-month revenue grew 8.9%. Management attributed growth primarily to organic therapy growth: chronic therapies grew at a high-single-digit rate in Q3 and low-double-digit rate for the nine-month period; acute therapies had mid-single-digit growth. Divestitures of respiratory assets and ALS and pre-term-labor therapies partly offset growth.
- Gross margin improved year over year, which management attributed to disciplined procurement, temporarily favorable therapy pricing dynamics, and efficient infusion-suite utilization. SG&A rose 11.4% in Q3 and 10.0% year to date, primarily due to salaries, benefits, and equity compensation.
- Nine-month net income includes a $106.0 million cash termination payment related to the canceled Amedisys merger, less $21.1 million of merger-related expenses. The filing states this transaction contributed $62.8 million to nine-month net income after expenses and taxes; it materially elevates the year-over-year earnings comparison. Q3 results did not include a comparable transaction.
- The company repurchased $175.0 million of stock during the first nine months, including 2.9 million shares in Q3. As of September 30, $75.0 million remained authorized under the $250.0 million program.
Outlook, risks, and other notable items
- Management expects existing cash, operating cash flows, and current liquidity to fund operating needs and planned capital expenditures over the next 12 months and beyond; future acquisitions or longer-term plans may require additional financing. No specific earnings or revenue guidance is provided in the filing text.
- Management noted that future COVID-19 variants could affect operations, but it could not confidently forecast the duration or financial impact. The COVID-19 public health emergency ended May 11, 2023.
- Revenue depends on payer reimbursement estimates and complex billing arrangements. The largest payer accounted for approximately 14% of revenue in Q3 and for the nine-month period. Four vendors supplied approximately 73% of pharmaceutical and medical supply purchases; a supplier change could disrupt service or revenue.
- The company is subject to routine legal proceedings, audits, and governmental inquiries. It does not expect pending matters, after reserves and indemnification, to materially affect its balance sheet, but acknowledges that unexpected judgments, fines, or settlements could adversely affect results or cash flows.
- The company reported no material changes to its previously disclosed risk factors or market-risk exposure. Management concluded disclosure controls were effective as of September 30, 2023.
Important facts for investors to verify
- How much of future margin performance depends on temporary favorable pricing and procurement conditions.
- The sustainability of organic therapy growth and the effects of divested therapies and payer reimbursement changes.
- Underlying earnings and cash generation excluding the Amedisys termination payment and related merger costs.
- Variable-rate debt exposure, interest costs, and available liquidity, including the term loan’s 8.20% stated rate.
- Execution and capital-allocation implications of the remaining share-repurchase authorization and potential acquisitions.